– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor– On track for mid-2022 full enrollment of HopES trial for SM-88 u.
Weekly Briefs: Biden describes 4 potential SCOTUS nominees; US liable for over $230M in church shooting abajournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from abajournal.com Daily Mail and Mail on Sunday newspapers.
PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.